Search the Newsreel

Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53

* Moleculin Biotech press release [https://seekingalpha.com/pr/20619725-moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued] (MBRX [https://seekingalpha.com/symbol/MBRX]): Q2 GAAP EPS of -$1.40 misses by $0.53. * As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as …

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Moleculin Biotech reported its second-quarter 2026 financial results, highlighting significant progress in its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory AML. Positive interim data showed complete remission rates three times higher than the control group, with enrollment on track for …

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX)

Moleculin Biotech (MBRX) stake capped at 4.99% under Intracoastal warrants

A Schedule 13G filing indicates that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively hold a beneficial ownership of 4.99% in Moleculin Biotech, Inc. (MBRX), amounting to 973,927 shares. This ownership includes shares held directly by Intracoastal and shares issuable upon …

Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants

Moleculin Biotech, Inc.'s CFO, Jonathan P. Foster, recently purchased 293,333 shares of common stock and 879,999 Series I Warrants in a public offering. These were acquired at a combined price of $0.75 per unit, with each unit comprising one share and three warrants. Following …

Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants

Moleculin Biotech, Inc.'s CEO, Walter V. Klemp, reported acquiring 533,333 shares of common stock and 1,599,999 Series I warrants in a public offering on August 3, 2026. The purchase was made at a combined price of $0.75 per common share and three accompanying warrants. …

Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants

Moleculin Biotech's Chief Science Officer, Donald H. Picker, recently purchased 173,333 shares of common stock and Series I Warrants to acquire an additional 519,999 shares. These transactions occurred on August 3, 2026, as part of a public offering at a combined price of $0.75 …

Price to sales forward of Moleculin Biotech, Inc. – LS:A41SET

This article provides financial information for Moleculin Biotech, Inc. (A41SET) on the TradingView platform. It specifically highlights the "Price to sales forward" metric for the company, accessible through the Lang & Schwarz Tradecenter. The content itself is minimalist, primarily serving as a header for …

Moleculin Biotech (NasdaqCM:MBRX) Stock Forecast & Analyst Predictions

Moleculin Biotech (MBRX) is forecast to increase earnings by 54.7% and revenue by 74.8% annually, with EPS expected to grow by 75.4%. The company's lead drug candidate, Annamycin, is progressing through pivotal Phase 2/3 MIRACLE trials for relapsed or refractory acute myeloid leukemia (R/R …

Moleculin Biotech completes $9.3M equity financing

Moleculin Biotech Raises $9.3 Million Equity; Signs Placement, Purchase and Lock-Up Agreements

Moleculin Biotech successfully completed a public offering, raising approximately $9.3 million gross. The company entered into a Placement Agency Agreement with Roth Capital Partners and a Securities Purchase Agreement with investors. Additionally, directors and officers have agreed to 60-day lock-up periods following the closing, …

Form 424B5 Moleculin Biotech Inc For: 3 August By Investing.com

This article announces the filing of Form 424B5 by Moleculin Biotech Inc., specifically for August 3rd. It is a brief, informative post from Investing.com, likely notifying investors of a regulatory filing by the company. The text reiterates the main point multiple times without further …

Moleculin Biotech, Inc. SEC Filing (Aug 3, 2026)

This article reports on a Moleculin Biotech, Inc. (MBRX) SEC filing, specifically an EFFECT filing, which had a neutral impact and sentiment. The filing pertains to the effectiveness of an S-1 registration statement for the company, dated July 31, 2026. The article also provides …

Moleculin Biotech Reports Positive Pivotal Phase 2/3 Trial Results for Annamycin in AML

Moleculin Biotech announced positive updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukaemia (R/R AML). The therapy showed strong remission rates, including in venetoclax-pretreated patients, …

Moleculin Biotech (MBRX) Registration filing Summary

Moleculin Biotech (MBRX) has filed a registration for a stock and warrant offering to raise $9.1 million, aiming to advance its late-stage cancer drug, Annamycin, for relapsed/refractory acute myeloid leukemia (AML). As of March 31, 2026, the company's net tangible book value was $4.0 …

Moleculin Biotech prices offering with warrants for 37,130,001 shares at $0.75 exercise price

Moleculin Biotech has priced a $9.3 million public offering that includes warrants to purchase up to 37,130,001 shares at an exercise price of $0.75 per share. The offering, which includes 12,376,667 common shares or pre-funded warrants, is expected to close around August 3, 2026. …

Moleculin Biotech updates Annamycin data, prices stock offering at $0.75

Moleculin Biotech has released updated preliminary blinded data from Part A of its MIRACLE trial for Annamycin, signaling stability in results despite the data remaining unblinded. Concurrently, the company priced a public offering at $0.75 per share, indicating confidence in the clinical trajectory to …

Moleculin Biotech (Nasdaq:MBRX) - Stock Analysis

Moleculin Biotech (MBRX) is a late-stage pharmaceutical company developing therapies for tumors and viruses, with its lead drug Annamycin undergoing Phase 2/3 trials for relapsed or refractory acute myeloid leukemia (R/R AML) and soft tissue sarcoma lung metastases. The company faces significant financial risks, …

Moleculin Biotech prices $9.3 million public offering

Moleculin Biotech (NASDAQ:MBRX) has priced a public offering of 12,376,667 shares of common stock and warrants for an additional 37,130,001 shares at $0.75 per share and warrant, totaling $9.3 million. The company plans to use the net proceeds to advance its lead drug candidate, …

Moleculin Announces Pricing of $9.3 Million Public Offering

Moleculin Biotech, Inc. announced the pricing of a $9.3 million public offering, selling 12,376,667 shares of common stock (or pre-funded warrants) and warrants to purchase up to 37,130,001 shares at $0.75 per unit. The offering is expected to close around August 3, 2026, with …

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Moleculin Biotech announced positive interim blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory AML. The trial showed a 37% composite complete remission (CRc) rate, with essentially identical rates for …

12 Health Care Stocks Moving In Friday's Pre-Market Session

This article identifies 12 healthcare stocks experiencing significant movement in pre-market trading on Friday. It lists several gainers, including Replimune Group and Moleculin Biotech, which saw substantial increases, and notable decliners such as Karyopharm Therapeutics and Bioage Labs. The movements are attributed to various …

Moleculin Biotech Files Registration Statement for Public Offering; Shares Fall

Moleculin Biotech has filed a registration statement with the SEC for a proposed public offering of its common stock and warrants, though the terms and size of the offering are yet to be determined. Following this announcement, the company's shares experienced a significant decline …

Form S-1 Moleculin Biotech Inc For: 29 July By Investing.com

This article announces the filing of Form S-1 by Moleculin Biotech Inc. on July 29. It briefly lists the company's stock symbol MBRX and its current performance percentage. The article is very short and serves primarily as a notification of the filing.

Moleculin Biotech Inc (MBRX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Moleculin Biotech Inc (MBRX), noting its current valuation score of 7.38, ranking 230 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -0.14 and mentions that relevant data …

Moleculin Biotech, Inc. Revenue Breakdown – NASDAQ:MBRX

This article provides access to the revenue breakdown for Moleculin Biotech, Inc. (NASDAQ: MBRX) on TradingView. It highlights the availability of financial data, segments, and regional performance details for the pharmaceutical company. The content primarily serves as a gateway to Moleculin Biotech's financial information …

Moleculin Biotech Inc (MBRX) Income Statement

This article provides the quarterly and annual income statements for Moleculin Biotech Inc (MBRX), offering detailed financial data such as total revenue, operating expenses, R&D expenses, and net income from FY2016Q1 through FY2026Q1. It also includes frequently asked questions about how to interpret these …

Enterprise value to EBIT forward of Moleculin Biotech, Inc. – NASDAQ:MBRX

The article focuses on the enterprise value to EBIT forward for Moleculin Biotech, Inc. with NASDAQ symbol MBRX. It appears to be a financial data page from TradingView, presenting financial metrics for the company. The content itself seems to be a placeholder or an …

Moleculin Biotech Inc (MBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Moleculin Biotech Inc (MBRX) stock information, focusing on its dividend history and stock split events. It indicates that the company has not distributed dividends in the past five years but lists several stock splits, primarily mergers, occurring in …

Moleculin Biotech Inc (MBRX) Institutional Confidence

This article from TradingKey provides an overview of Moleculin Biotech Inc.'s (MBRX) institutional confidence score and shareholder activity. It lists key institutional shareholders, the number of shares they hold, and the percentage change in their holdings, highlighting recent activity from firms like UBS Financial …